Moleculin Biotech (NASDAQ:MBRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a research note published on Thursday morning. The brokerage issued a sell rating on the stock.

MBRX has been the subject of a number of other reports. Maxim Group cut shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a research note on Wednesday, February 12th. HC Wainwright reissued a “buy” rating and set a $8.00 price objective on shares of Moleculin Biotech in a research note on Monday, March 3rd.

Moleculin Biotech Price Performance

Shares of MBRX opened at $1.16 on Thursday. The firm has a 50 day simple moving average of $1.44 and a 200-day simple moving average of $2.08. Moleculin Biotech has a 1-year low of $0.40 and a 1-year high of $8.85.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.